Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies

Regulations by 2FIRSTS.ai
Jun.24.2024
Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies
Australia government withdraws e-cigarette sales plan, allowing non-prescription purchase at pharmacies. Health Minister Mark Butler reached agreement with Greens.

According to The Sydney Morning Herald on June 24th, the Australian government has withdrawn its plan to allow e-cigarettes to be sold commercially. E-cigarettes will not require a prescription to be purchased in pharmacies.

 

Minister of Health Mark Butler reached an agreement with the Green Party on Monday, June 24th, to relax the ban on e-cigarettes scheduled to take effect in July. This was in order to pass legislation in the Senate to prohibit retail sales, as the initially stricter proposal did not have the support of the majority of senators.

 

According to sources familiar with the agreement, after the ban on e-cigarettes takes effect in July, consumers will still need a doctor's prescription to purchase e-cigarettes. However, in the future, adults will not need a prescription from a general practitioner to buy e-cigarettes from pharmacies. They will only need to speak with a pharmacist and can purchase them over the counter.

 

At the same time, individuals under the age of 18 are allowed to purchase e-cigarettes with a prescription from a clinician if deemed appropriate.

 

The government has promised to provide additional funding to support young people in quitting e-cigarettes.

 

E-cigarettes sold in pharmacies will still be regulated and must comply with standard packaging requirements.

 

Butler's adjustment is a concession to the substantial political capital invested in the success of the e-cigarette ban. He will announce the full details of the changes later today.

 

Butler previously proposed the idea of allowing people to purchase e-cigarettes from pharmacies without a prescription, but he stated that this would only be considered if the prescription drug model is not successful.

 

He stated in November of last year,

 

Health ministers are interested in exploring whether e-cigarettes can be provided solely by pharmacists in pharmacies, where similar products are often located behind the counter and require interaction with a pharmacist but not a doctor's prescription.

 

We have not made a decision yet, but I have said that if the proposed reform does not adequately ensure that people with genuine treatment needs can access e-cigarettes, we will consider other options.

 

Both the Greens and the National Party have expressed doubt about the proposal put forward by the Labor Party to ban all retail sales of e-cigarettes and require a prescription from a general practitioner to obtain them from a pharmacy. This is a stricter version of the law first proposed by former Coalition Health Minister Greg Hunt in 2021.

 

The Green Party and the two major political parties are aligned in their desire to prevent children from purchasing e-cigarettes from unlicensed stores.

 

However, the Greens' health spokesperson, Jordon Steele-John, expressed concerns about the difficulties and costs of quitting smoking for those who need to make an appointment with a general practitioner in order to get a prescription. The Department of Health's analysis of Butler's original plan indicates that 450,000 Australians per year will seek e-cigarette prescriptions, requiring nearly one million visits to general practitioners.

 

John also expressed skepticism towards the prohibition model, pointing out that drug bans have proven to be ineffective.

 

Many young Australians are using e-cigarettes, banning the sale of e-cigarettes could potentially become a political issue.

 

No one should be punished for personal use of e-cigarettes. Prohibition policies for drugs have failed. Many people under the age of 18 are becoming addicted to nicotine. We need to ensure there are proper resources in place to help these individuals quit using e-cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
PMI Expands Its Second Global and First Asian Business Services Hub in the Philippines, Serving 160 Markets and Scaling Up AI Capabilities
Philip Morris International's PMI Business Solutions Philippines has expanded its global business services hub in Makati and plans to add more than 80 positions. Established in 2021 primarily to provide finance and IT support to about 20 markets, the center now employs 519 professionals delivering roughly 600 services across 160 markets. Its functions now span finance, human resources, IT, commercial operations, data analytics, supply chain and project management. PMI says the hub's next phase will focus on AI-enabled and higher-value work. The company did not disclose the size or investment cost of the expansion.
Sep.24
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
British American Tobacco's Japanese subsidiary, BAT Japan, launched VELO Mango Ice Medium on November 2, 2026, with distribution expanding to selected 7-Eleven, FamilyMart, NewDays and Seicomart stores from November 3. The new oral tobacco product contains 15 pouches per can and retails for ¥380, featuring a mango and cooling flavor profile at Medium intensity. At the same time, BAT Japan raised prices on multiple existing VELO products from ¥360 to ¥380 per can and withdrew selected SKUs from convenience store distribution without discontinuing them entirely. The changes affect product assortment, pricing and retail channel allocation.
product
Nov.04